Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial

January 15, 2021 By Law Offices of Thomas J. Lamb, P.A.

Background:  A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Talc-Based Beauty Products Found to be Contaminated With Asbestos

January 15, 2021 By Law Offices of Thomas J. Lamb, P.A.

Talc-based beauty products have been found to be contaminated with asbestos according to some recent news headlines.  How can this be? For years, cosmetics and personal care products have included a mineral ingredient called talc in their manufacturing process. Talc’s original intention was to improve the texture and feel of products, … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos lawsuits, asbestos-infused talc, mesothelioma, mesothelioma lawsuits, talc

Chemo-Free Regimen Boosts OS in Mesothelioma

November 23, 2020 By Law Offices of Thomas J. Lamb, P.A.

A chemotherapy-free combination significantly improved overall survival (OS) as initial therapy for unresectable malignant pleural mesothelioma (MPM), a large randomized trial showed. Patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) had a media OS of 18.1 months versus 14.1 months for patients randomized to chemotherapy. The … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Dying Patients Denied Justice Amid COVID-Related Court Delays

November 13, 2020 By Law Offices of Thomas J. Lamb, P.A.

Terminally ill plaintiffs, who were supposed to be guaranteed expedited trials in light of their deteriorating medical conditions, are still waiting for their day in court, according to an NBC Bay Area investigation. [ Terminally ill plaintiffs ] who are dying are supposed to be granted preferential treatment when it comes to scheduling their … [Read more...]

Filed Under: Mesothelioma Tagged With: asbestos lawsuits, mesothelioma lawsuits

Biomarker candidates could aid in earlier diagnosis of mesothelioma

October 22, 2020 By Law Offices of Thomas J. Lamb, P.A.

Mesothelioma is a deadly cancer mainly caused by exposure to asbestos fibers. Unfortunately, mesothelioma is generally diagnosed at an already advanced stage and none of the therapeutic strategies tried so far is able to eradicate the disease. So new biomarkers that could help to identify the disease at an earlier stage are urgently … [Read more...]

Filed Under: Asbestos, Mesothelioma

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

October 16, 2020 By Law Offices of Thomas J. Lamb, P.A.

Background:  Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. Patients and … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

October 2, 2020 By Law Offices of Thomas J. Lamb, P.A.

Background:  There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during … [Read more...]

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

FDA clears IND application for CAR T-cell therapy for advanced mesothelioma

September 22, 2020 By Law Offices of Thomas J. Lamb, P.A.

The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy [ or CAR T-cell therapy ] for the treatment of advanced mesothelioma, according to the agent’s manufacturer. ATA2271 (Atara Biotherapeutics) is an autologous CAR T-cell therapy that targets the mesothelin antigen expressed on the … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

September 15, 2020 By Law Offices of Thomas J. Lamb, P.A.

Data from a Phase I study published last week in the Journal of Clinical Oncology showed that Bayer’s investigational compound anetumab ravtansine (BAY 94-9343), an antibody-drug conjugate comprising an anti-mesothelin antibody linked to maytansinoid DM4, was well tolerated in [ cancer ] patients with advanced, metastatic, or recurrent solid tumors … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup

September 1, 2020 By Law Offices of Thomas J. Lamb, P.A.

Purpose: Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate, whether activating mutations in the telomerase reverse transcriptase (TERT) gene promoter are present in [malignant pleural mesothelioma (MPM)] and … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, pleural mesothelioma

  • 1
  • 2
  • 3
  • …
  • 21
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.